FDA Approves mFLUSIVA, First mRNA Seasonal Flu Vaccine in the U.S.

The 2026–2027 respiratory virus season will feature a fundamentally new tool in the public health arsenal. On August 5, 2026, the Food and Drug Administration officially approved mFLUSIVA, making it the first mRNA-based seasonal influenza vaccine authorized for use in the United States.[1][5]

Manufactured by Moderna, the vaccine is fully approved for adults aged 50 and older. The agency also granted an accelerated approval for adults aged 65 and older, allowing the shot to be deployed widely while confirmatory trials are completed.[1][3]

The approval rests on a massive Phase 3 clinical trial involving more than 40,000 participants across 11 countries. In that study, mFLUSIVA demonstrated a 26.6% greater relative vaccine efficacy against confirmed influenza compared to a standard-dose licensed flu vaccine.[2][4]

For decades, traditional flu vaccines have relied on inactivated viruses grown in chicken eggs or mammalian cells. This process is reliable but notoriously slow, requiring global health authorities to predict which flu strains will circulate roughly six months before the winter season begins.[1][4]

When the virus mutates during that six-month window, the resulting vaccine can be a poor match, leading to seasons with high hospitalization rates and diminished vaccine effectiveness. Over the past 15 years, seasonal flu vaccines have been anywhere from 20% to 60% effective at preventing serious illness.[6]

The mRNA platform bypasses the egg-incubation process entirely. Instead of an inactivated virus, the vaccine delivers a small snippet of genetic code encapsulated in a lipid nanoparticle. This code instructs the body's own cells to produce hemagglutinin, a harmless protein found on the surface of the influenza virus.[1][3]

The immune system recognizes this protein as an invader and builds a defense against it. Because mRNA vaccines can be manufactured much faster than conventional shots, strain selection could theoretically be delayed until just two months before flu season, drastically improving the odds of a precise match.[3]

Despite the promising efficacy data, the vaccine's rollout comes with clinical caveats, particularly for the most vulnerable demographic. The FDA's accelerated approval for the 65-and-older cohort is based on immune response markers rather than confirmed clinical outcomes against the high-dose vaccines typically recommended for seniors.[2][5]

Without head-to-head data comparing mFLUSIVA to these enhanced, high-dose options, some clinicians remain cautious. Public health experts emphasize that while the mRNA shot is a powerful new option, it does not automatically replace the established high-dose vaccines for the elderly until further real-world evidence is gathered.[1][4]

Patients opting for the new vaccine should also expect a different reactogenicity profile. Trial participants receiving mFLUSIVA reported side effects at roughly twice the rate of those receiving standard flu shots.[1]

These side effects—which include injection site pain, fatigue, headache, and muscle aches—are similar to the temporary, mild-to-moderate responses familiar to anyone who received an mRNA COVID-19 vaccine. Serious adverse events remained rare across all trial groups.[1][6]

The regulatory journey to this milestone was unusually turbulent. In February 2026, the FDA issued a "refusal-to-file" letter, initially declining to even review Moderna's application due to disagreements over the trial design for the older cohort.[2][3]

The dispute sparked a rare public disagreement between the manufacturer and the regulator, but the FDA reversed its stance less than a week later, agreeing to review the data in time for the upcoming winter season.[2]

Beyond influenza, the approval validates the broader utility of the mRNA platform for respiratory diseases. Biotech analysts note that this clearance paves the way for combination vaccines—such as a single shot targeting both COVID-19 and influenza—which are already moving through the regulatory pipeline.[3][5]

As mFLUSIVA reaches clinics this fall, the consensus among physicians is practical: the most important decision for the 2026–2027 season is to get an appropriate flu vaccine, rather than waiting for any single "perfect" technology.[4]